Logo

BRAF Biomarkers

News and reporting on BRAF biomarkers.

Kinnate Biopharma, Guardant Health Partner for Study of BRAF Mutations in Solid Tumors

Preliminary findings indicate that about half of the 6,000 patients with BRAF alteration-positive cancers harbored Class II and III alterations.

MapKure, Personalis Partner to Screen Patients for BRAF Inhibitor Trial

Personalis plans to develop a companion diagnostic to MapKure's BRAF inhibitor, BGB-3245, once biomarkers have been identified in the study.

Novellus, Tempus Partner to Enroll Patients in BRAF Inhibitor Clinical Trial Program

The Jerusalem-based drug developer is studying PLX8394 in patients with BRAF V600-mutated gliomas and solid tumors with non-V600 mutations. 

Melanoma Treatment Stage Affects Ability of Liquid Biopsy to Predict Immunotherapy Benefit
Premium

Researchers showed that ctDNA levels predicted who would respond to first-line immune checkpoint inhibition but were not useful in second-line therapy.

Strata Oncology, BioMed Valley Discoveries Partner on Patient Enrollment for Ulixertinib Study

Through the partnership, Strata will use its next-generation sequencing test to identify advanced cancer patients with mutations in the MAPK signaling pathway.

Apr 27, 2020

Amid COVID-19, Lower Cancer Diagnosis Rates Mean Fewer Patients Getting Molecular Tests, Treatment
Premium

Feb 13, 2020

Genetron Health Obtains Regulatory Approval in China for NGS Instrument, Lung Cancer Panel

Jan 27, 2020

Colon Cancer Biomarker Undertesting Rates in Real-World Data Points to Precision Oncology Barriers
Premium

Sep 23, 2019

Global Survey Reveals Suboptimal Molecular Testing Access in Lung Cancer Despite Broad Guidelines
Premium

Jun 18, 2019

Next-Generation Sequencing of Pediatric Cancer Patients Could Transform Treatment Paradigms
Premium

Jun 6, 2019

TAPUR Study Investigators Report First Positive Findings, Pursuing Tissue-Agnostic Cohorts
Premium

May 16, 2019

NCI Pediatric MATCH Trial Interim Data Shows 24 Percent of Patients Eligible for Targeted Therapy
Premium

May 9, 2019

Liquid Biopsy of Melanoma Surgery Drainage Fluid Shows Promise for Recurrence Monitoring
Premium

Jan 25, 2019

MethylDetect Looks to Leverage High-Resolution Melt Tech for Oncology Assay Development
Premium

Jan 10, 2019

Melanoma BRAF Mutation Type May Affect Response to Targeted Treatments, Immunotherapy

Aug 7, 2018

Researchers Integrate Genotyping Assay, Drug Delivery Tech for Precision Glioma Treatment
Premium

Jun 18, 2018

Recurrent Rearrangements Identified in Rare Infant Soft Tissue Tumors

May 31, 2018

PanDrugs System Aims to Advance Precision Cancer Care by Matching Treatments to Mutations
Premium

Nov 6, 2017

Genentech's Zelboraf Gets FDA Approval in BRAF Mutation-Positive Erdheim-Chester Disease

Jun 22, 2017

Thermo Fisher Next-Gen Sequencing Panel Wins FDA Approval as Companion Test

Jun 22, 2017

Quest Diagnostics to Expand Advanced Cancer Care to Community Oncologists Through Recent Acquisitions
Premium

May 1, 2017

BRAF Proficiency Testing Reporting Adequate But Could Improve, Analysis Finds

Feb 16, 2017

Head-to-Head Comparison of BRAF Assays Yields Clues About Ideal Use in Guiding Melanoma Therapy
Premium

Dec 15, 2016

Biocartis Gets CE Mark for Idylla NRAS-BRAF Mutation Test

Sep 6, 2016

Combined PNA Clamp, Sensor PCR Method Shows Promise for Detection of BRAF Mutations
Premium

Breaking News
The Scan

Call for a Different Tack

Experts weigh the value of recent experiments testing genetically modified pig kidneys using brain-dead individuals, according to Nature News.

Wastewater Warning

The New York Times reports that wastewater surveillance in some parts of the US point to a possible surge.

Can't Get in the Program

Due to the Northern Ireland protocol dispute, the European Union is preventing UK researchers from joining the Horizon Europe research program, the Times of London reports.

Science Paper on Spatial-Controlled Genome Editing

In Science this week: approach to enable a CRISPR-Cas13a-based system to be used as a cancer therapy.